Baillie Gifford & Co. Purchases 60,789 Shares of RxSight, Inc. (NASDAQ:RXST)

Baillie Gifford & Co. increased its position in RxSight, Inc. (NASDAQ:RXST - Free Report) by 17.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 419,004 shares of the company's stock after buying an additional 60,789 shares during the period. Baillie Gifford & Co. owned 1.13% of RxSight worth $20,711,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. M&G Plc bought a new stake in RxSight during the 1st quarter worth approximately $7,354,000. Vanguard Group Inc. grew its holdings in RxSight by 2.7% during the first quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company's stock worth $78,634,000 after buying an additional 40,500 shares in the last quarter. Algert Global LLC purchased a new stake in RxSight in the 2nd quarter valued at $2,488,000. Bank of New York Mellon Corp lifted its stake in RxSight by 17.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 119,493 shares of the company's stock valued at $7,190,000 after acquiring an additional 17,368 shares in the last quarter. Finally, Caxton Associates LP purchased a new position in RxSight during the 1st quarter worth $1,208,000. 78.78% of the stock is owned by institutional investors.

RxSight Stock Performance

Shares of RXST traded down $0.81 during mid-day trading on Wednesday, hitting $44.65. The stock had a trading volume of 538,726 shares, compared to its average volume of 486,786. RxSight, Inc. has a 52 week low of $26.20 and a 52 week high of $66.54. The business has a fifty day moving average price of $50.85 and a 200-day moving average price of $53.46.

Insider Buying and Selling

In other RxSight news, insider Ilya Goldshleger sold 3,100 shares of the company's stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $52.67, for a total transaction of $163,277.00. Following the sale, the insider now directly owns 42,246 shares of the company's stock, valued at $2,225,096.82. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders sold 43,415 shares of company stock valued at $2,178,847. 9.36% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Jefferies Financial Group started coverage on shares of RxSight in a research report on Tuesday, October 29th. They set a "buy" rating and a $72.00 price target on the stock. Stifel Nicolaus dropped their target price on shares of RxSight from $70.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, August 6th. Oppenheimer reduced their target price on RxSight from $72.00 to $65.00 and set an "outperform" rating for the company in a report on Tuesday, August 6th. Wells Fargo & Company decreased their price target on RxSight from $68.00 to $54.00 and set an "overweight" rating for the company in a research report on Tuesday, August 6th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $61.63.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.